Mesoblast Ltd
MESOHealthcare|Biotechnology|Australia
$15.46
+0.60 (+4.04%)
Tangible Book
$0.07
Clinical Trials (42)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06325566 Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain | Degenerative Disc Disease | P3 | Active | 300 | RCT, Double-blind | Rexlemestrocel-L + HA mixture, Saline |
| NCT02652130 Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD | Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease | P3 | Completed | 32 | Open-label | Remestemcel-L |
| NCT00562497 Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD) | Graft Versus Host Disease | P3 | Completed | 192 | RCT, Double-blind | Prochymal® |
| NCT00543374 Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease | Crohn's Disease | P3 | Completed | 98 | RCT, Double-blind | Placebo, PROCHYMAL adult human mesenchymal stem cells |
| NCT00366145 Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD) | Graft Versus Host Disease | P3 | Completed | 260 | RCT, Double-blind | Prochymal®, Placebo, Standard of Care for GVHD |
| NCT00482092 Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease | Crohn's Disease | P3 | Completed | 330 | RCT, Double-blind | Prochymal®, Placebo |
| NCT02032004 Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure | Chronic Heart Failure | P3 | Completed | 565 | RCT, Double-blind | Rexlemestrocel-L |
| NCT01233960 Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease | Crohn's Disease | P3 | Completed | 73 | Open-label | Prochymal® |
| NCT02336230 A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) | Grade B aGVHD, Grade C aGVHD | P3 | Completed | 55 | Open-label | remestemcel-L |
| NCT02412735 Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain | Degenerative Disc Disease | P3 | Completed | 404 | RCT, Double-blind | Rexlemestrocel-L, Rexlemestrocel-L + HA Mixture, Placebo |
| NCT01854567 P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | P3 | Completed | 49 | RCT, Open-label | Infusion of one MPC expanded cord unit and one unexpanded cord unit, Infusion of two unexpanded cord blood units. |
| NCT07568535 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease | GVHD - Graft-Versus-Host Disease | P3 | Not Yet Recruiting | 180 | RCT, Double-blind | Remestemcel-L-rknd |
| NCT04371393 MSCs in COVID-19 ARDS | Mesenchymal Stromal Cells, Remestemcel-L | P3 | Terminated | 223 | RCT, Double-blind | Remestemcel-L, Placebo |
| NCT01781390 Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction | Acute Myocardial Infarction | P2 | Completed | 106 | RCT, Double-blind | Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M |
| NCT00877903 Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI) | Myocardial Infarction | P2 | Completed | 220 | RCT, Double-blind | Prochymal®, Placebo |
| NCT00225095 A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy | Recovery Following Partial Medial Meniscectomy | P1P2 | Completed | 60 | RCT, Double-blind | Mesenchymal Stem Cells, Hyaluronan |
| NCT00810212 Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion | Degenerative Disc Disease, Degenerative Spondylolisthesis | P1P2 | Withdrawn | — | RCT, Open-label | PLF with NeoFuse, PLF with NeoFuse, PLF with NeoFuse |
| NCT00721045 A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure | Heart Failure | P2 | Completed | 60 | RCT, Single-blind | Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs) |
| NCT00136903 Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) | Graft Vs Host Disease | P2 | Completed | 32 | RCT, Open-label | Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone, Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil |
| NCT00996073 Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion | Degenerative Disc Disease, Degenerative Spondylolisthesis | P2 | Completed | 24 | RCT, Single-blind | Lumbar Interbody Fusion with Autograft, Lumbar Interbody Fusion with NeoFuse, Lumbar Interbody Fusion with NeoFuse |
| NCT01843387 Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy | Diabetic Nephropathy, Type 2 Diabetes | P1P2 | Completed | 30 | RCT, Double-blind | Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs) |
| NCT01851070 A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor | Rheumatoid Arthritis | P2 | Completed | 48 | RCT, Double-blind | Allogeneic Mesenchymal Precursor Cells, Normal Saline |
| NCT01106417 Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion | Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis | P1P2 | Completed | 12 | RCT, Single-blind | NeoFuse |
| NCT01097486 Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy | Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis | P2 | Completed | 24 | RCT, Single-blind | NeoFuse |
| NCT01290367 Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain | Degenerative Disc Disease | P2 | Completed | 100 | RCT, Double-blind | Single Dose MPCs Injection, Single Dose MPCs Injection |
| NCT00294112 Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease | Crohn's Disease | P2 | Completed | 10 | RCT, Open-label | Prochymal™ adult human mesenchymal stem cells, adult human mesenchymal stem cells |
| NCT01088191 Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction | Anterior Cruciate Ligament Injury, Osteoarthritis | P1P2 | Completed | 17 | RCT, Double-blind | MSB-CAR001 Combined With Hyaluronan, Hyaluronan |
| NCT01576328 Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes | Type 2 Diabetes | P1P2 | Completed | 61 | RCT, Single-blind | Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs) |
| NCT00702741 Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy | Recovery Following Partial Medial Meniscectomy | P1P2 | Completed | 55 | RCT, Double-blind | Chondrogen, Chondrogen, Placebo |
| NCT00081055 OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies | Graft Versus Host Disease, Leukemia | P2 | Withdrawn | — | RCT, Double-blind | autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide, cyclosporine, methotrexate |
| NCT00690066 PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) | Type 1 Diabetes Mellitus, Type 1 Diabetes | P2 | Completed | 63 | RCT, Double-blind | PROCHYMAL®, Placebo |
| NCT00549913 Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF) | Degenerative Disc Disease, Spondylolisthesis | P1P2 | Completed | 6 | RCT, Open-label | NeoFuse |
| NCT00683722 PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema | P2 | Completed | 62 | RCT, Double-blind | Prochymal™, Placebo |
| NCT00284986 Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants | Graft Versus Host Disease | P2 | Completed | 11 | Open-label | Prochymal |
| NCT04543994 Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) | Ulcerative Colitis | P1P2 | Terminated | 7 | RCT, Single-blind | Remestemcel-L, Remestemcel-L |
| NCT04548583 Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis | Crohn Colitis | P1P2 | Terminated | 7 | RCT, Single-blind | Remestemcel-L, Remestemcel-L |
| NCT00114452 Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction | Myocardial Infarction | P1 | Completed | 60 | RCT, Double-blind | Provacel, Placebo |
| NCT04456439 Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) | Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) | NO_LONGER_AVAILABLE | — | — | Remestemcel-L, Hydrocortisone, Diphenhydramine | |
| NCT00759018 Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD | Graft vs Host Disease, Graft-Versus-Host Disease | NO_LONGER_AVAILABLE | — | — | remestemcel-L | |
| NCT00826046 Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD) | Graft-Versus-Host Disease | NO_LONGER_AVAILABLE | — | — | Prochymal® | |
| NCT04366830 Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection | Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19 | NO_LONGER_AVAILABLE | — | — | Remestemcel-L | |
| NCT01510431 Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease | Crohn's Disease | NO_LONGER_AVAILABLE | — | — | PROCHYMAL (remestemcel-L) |